Shopping Cart
- Remove All
- Your shopping cart is currently empty
12(S)-HETrE is an endogenous metabolite produced by oxidation of ω-6 PUFA dihomo-γ-linolenic acid (DGLA) by 12-lipoxygenase (12-LOX) in platelets, which acts on Gαs-coupled G-protein-coupled receptors, has antithrombotic properties, and has potential therapeutic use in cardiovascular disease. 12(S)-HETrE is reported to inhibit agonist-mediated platelet activation (IC50 = 40 μM), α granule secretion, integrin αIIbβ3 activation, Rap1 activation, and thrombin-induced clot retraction in vitro.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 μg | $230 | 35 days | |
50 μg | $438 | 35 days | |
100 μg | $828 | 35 days |
Description | 12(S)-HETrE is an endogenous metabolite produced by oxidation of ω-6 PUFA dihomo-γ-linolenic acid (DGLA) by 12-lipoxygenase (12-LOX) in platelets, which acts on Gαs-coupled G-protein-coupled receptors, has antithrombotic properties, and has potential therapeutic use in cardiovascular disease. 12(S)-HETrE is reported to inhibit agonist-mediated platelet activation (IC50 = 40 μM), α granule secretion, integrin αIIbβ3 activation, Rap1 activation, and thrombin-induced clot retraction in vitro. |
In vitro | 12(S)-HETrE (20, 40 μM) treated platelets, and at a concentration of 40 μM, platelets are sensitive to them, which can have an inhibitory effect on platelets. [1] |
Molecular Weight | 322.48 |
Formula | C20H34O3 |
Cas No. | 72710-10-2 |
Smiles | C(\[C@H](C/C=C\CCCCC)O)=C/C=C\CCCCCCC(O)=O |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
Solubility Information | 0.1 M Na2CO3: 4.00 mg/mL (12.40 mM), Sonication is recommended. PBS (pH 7.2): < 1 mg/ml (slightly soluble or insoluble), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
0.1 M Na2CO3
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.